Zymeworks Inc.

Listed Company

ZYMECIK 0001937653NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$105.97M

Net Income

$-81.13M

Total Assets

$346.53M

Equity

$268.50M

Shares Out

73.02M

Op. Cash Flow

$-33.01M

ZYME$26.30+104.19% · past yearDBEQ Basic

Daily closing prices

Business

Zymeworks is a biotechnology company that discovers and develops multifunctional biotherapeutics for cancer, inflammation, and autoimmune disease using proprietary platforms including Azymetric, ADC, EFECT, and ProTECT. Key programs include zanidatamab (Ziihera), approved for HER2-positive biliary tract cancer, and pasritamig, a T cell engager in Phase 3 development. The company partners with major pharmaceutical companies including Jazz, BeOne, BMS, GSK, Daiichi Sankyo, J&J, and Merck for development and commercialization, generating royalty streams.

Summary from 10-K filed 2026-03-02

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development collaborations (note 11)	106	76	76	412	27
Research and development	137	135	144	209	—
General and administrative	62	62	70	73	43
Impairment on IPR&D (note 6)	0	17	0	0	—
Total operating expenses	199	213	214	282	242
Loss from operations	−93	−137	−138	131	−216
Interest income	13	20	20	4	2
Other (expense) income, net (note 12)	−559,000	558,000	−894,000	1	1
Total other income, net	13	20	19	5	3
Loss before income taxes	−80	−117	−119	135	−212
Income tax (expense) recovery (note 13)	−1	−6	568,000	−11	516,000
Net loss	−81	−123	−119	124	−212
Unrealized income (loss) on available for sale securities, net of tax of nil (note 5)	873,000	−349,000	56,000	0	0
Total other comprehensive income (loss)	873,000	−349,000	56,000	0	0
Comprehensive loss	−80	−123	−119	124	−212
Basic (in dollars per share)	−1.08	−1.62	−1.72	1.91	−4.11
Diluted (in dollars per share)	−1.08	−1.62	−1.72	1.9	−4.61
Basic (in shares)	75	76	69	65	52
Diluted (in shares)	75	76	69	65	52

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	41	66	158	401	202
Short-term marketable securities (note 5)	188	160	217	—	—
Accounts receivable	5	56	19	33	16
Prepaid expenses and other current assets	15	19	19	19	20
Total current assets	249	300	413	545	288
Long-term marketable securities (note 5)	42	98	82	—	—
Long-term prepaids and other assets	7	9	8	—	—
Deferred tax asset (note 13)	5	4	4	1	3
Property and equipment, net (note 7)	16	18	20	25	23
Operating lease right-of-use assets (note 14)	16	17	18	23	27
Intangible assets, net (note 8)	1	5	8	9	4
Goodwill (note 6)	12	12	12	12	12
Total assets	347	463	581	649	389
Accounts payable and accrued liabilities (note 9)	36	60	46	87	63
Income tax payable (note 13)	83,000	128,000	2	840,000	0
Current portion of operating lease liability (note 14)	3	3	4	3	1
Deferred revenue and other consideration (note 11)	2	26	4	2	0
Total current liabilities	42	88	56	96	72
Long-term portion of operating lease liability (note 14)	15	16	22	25	31
Deferred revenue (note 11)	15	15	33	31	33
Other long-term liabilities (note 9)	278,000	923,000	2	3	3
Deferred tax liability (note 13)	6	5	3	2	2
Total liabilities	78	124	116	156	140
Common shares, $0.00001 par value; 900,000,000 authorized shares of common stock at December 31, 2025 and December 31, 2024 (74,638,413 and 68,964,319 shares issued and outstanding at December 31, 2025 and 2024, respectively (note 10b).	1,105	1,016	997	886	741
Preferred shares, $0.00001 par value; 100,000,000 authorized shares of preferred stock, out of which, one share of preferred stock is a share of Special Voting Preferred Stock and outstanding as of December 31, 2025 and December 31, 2024 (note 10b).	0	0	0	0	0
Exchangeable shares, no par value, 553,184 issued and outstanding shares at December 31, 2025 (December 31, 2024: 570,637) (note 10b).	8	8	9	20	0
Additional paid-in capital	115	152	142	152	198
Accumulated other comprehensive loss	−6	−7	−7	−7	−7
Accumulated deficit	−953	−830	−677	−559	−683
Total stockholders equity	269	339	465	493	249
Total liabilities and stockholders equity	347	463	581	649	389
Commitments and contingencies (note 15)	—	—	—	—	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation of property and equipment (note 7)	4	4	7	6	4
Amortization of intangible assets (note 8)	4	4	3	1	3
Stock-based compensation (note 10e)	28	18	8	4	11
Amortization and impairment of operating lease right-of-use assets	3	3	7	5	3
Deferred income tax expense (recovery) (note 13)	945,000	691,000	−757,000	2	−953,000
Change in fair value of contingent consideration liability (note 15)	0	−2	630,000	−250,000	213,000
Change in fair value of investments in equity instruments	0	0	667,000	0	−167,000
Unrealized foreign exchange loss (gain)	532,000	−1	−31,000	−2	−433,000
Accounts receivable	51	−36	14	−18	−266,000
Prepaid expenses and other current assets	7	−2	4	−2	−16
Accounts payable and accrued liabilities	−24	14	−45	26	16
Operating lease liabilities	−3	−8	−4	−4	−26,000
Deferred revenue and other consideration	−23	4	4	0	0
Income taxes payable	−45,000	−2	970,000	840,000	0
Net cash used in operating activities	−33	−110	−118	144	−192
Proceeds from issuance of common stock under at-the-market program and from public offerings, net of issuance costs (notes 10a)	0	0	26	108	0
Private placement (note 10a)	5	0	50	0	0
Issuance of common stock on exercise of stock options (note 10e)	17	9	5	255,000	6
Issuance of common stock through employee stock purchase plan (note 10f)	1	930,000	820,000	1	2
Purchases of common stock for retirement (note 10c)	−42	−30	0	0	—
Deferred financing fees	−181,000	−174,000	−53,000	−596,000	−470,000
Net cash (used in) / provided by financing activities	−19	−20	82	109	8
Purchases of marketable securities	−196	−284	−553	−113	−35
Proceeds from marketable securities	225	326	350	72	193
Acquisition of property and equipment	−2	−2	−2	−8	−12
Acquisition of intangible assets	−831,000	−1	−2	−5	−881,000
Net cash provided by / (used in) investing activities	27	39	−207	−54	145
Effect of exchange rate changes on cash and cash equivalents	−45,000	286,000	354,000	203,000	−325,000
Net change in cash and cash equivalents	−25	−91	−243	199	−40
Net cash paid during the year for income taxes	1	3	165,000	10	—
Leased assets obtained in exchange for operating lease liabilities	2	644,000	2	72,000	25
Issuance of common stock upon exercise of pre-funded warrants (note 10d)	50	0	0	—	—
Purchases of common stock not settled	464,000	0	0	—	—
Acquisition of property and equipment and intangible assets in accounts payable and accrued liabilities	0	0	122,000	957,000	2

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Zymeworks Inc.'s CIK number?

Zymeworks Inc.'s SEC CIK number is 0001937653 (1937653). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Zymeworks Inc.'s SEC filings?

All of Zymeworks Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Zymeworks Inc. last report earnings?

Zymeworks Inc. (ZYME) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001937653-26-000033). This is Zymeworks Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Zymeworks Inc.'s most recent earnings 8-K?

Zymeworks Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001937653-26-000033. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Zymeworks Inc.'s latest earnings 8-K →
Look up any company's CIK number →